ARC Medical Devices

Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs) for the treatment of a broad range of cancers. Its proprietary technology platform supports a unique, multi-methodology treatment paradigm that can precisely deliver potent cell-killing agents for cancer as well as actively alter the immunosuppressive tumor micro-environment without harming healthy cells. The company was founded in 2012 and based in Toronto, Ontario, Canada.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube, and Instagram.

Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies for medical conditions. These therapies are developed from the patient's own blood, making it a minimally invasive treatment option. The company's main product, ACP-01, is currently in Phase II clinical trials for critical limb ischemia. In addition to this product, Hemostemix is also working on developing other types of cell products, including bone cell precursors, myocardial cell precursors, and neural cell precursors.

Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis products. It employs a system based on data and experiments to present highly developed cannabinoid solutions in various product categories such as API, medical, pharmaceutical, and derma cosmetics. With vertical integration and a global presence, Avicanna is determined to harness the findings of scientific research on cannabis-based products with the aid of its internal research platforms and partnerships with renowned research institutions worldwide. Established in 2016, the company has its headquarters in Toronto, Ontario, Canada.

Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for dermatological and anorectal ailments. Their primary goal is to develop innovative and effective alternatives to steroids for conditions like Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. The company's main product, EB01, is a groundbreaking non-steroidal anti-inflammatory molecule designed to treat allergic contact dermatitis. Numerous clinical studies have already shown significant improvements resulting from its use.

ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that target Myeloid cells.

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.

Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and bio-technology companies during FDA clinical trials.

ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical purposes. Using advanced technology and artificial intelligence, we develop dynamic peptides that deliver drugs directly to their target, surpassing other methods of drug delivery. By breaking new ground in therapeutics, we are revolutionizing drug development and providing hope to patients with previously incurable illnesses. Our team at ProteinQure is made up of experts in experimental and computational biology, machine learning, and software engineering, bringing together a diverse range of skills and knowledge.

Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's factories, enzymes, and renewable electricity to produce carbon negative chemicals. Our breakthrough technology eliminates emissions by transforming CO2 into strategic chemicals, materials and fuels that today are made from fossil fuels. Carbon utilization fundamentally changes how we recycle emissions into products so that we can address climate change and reverse the carbon imbalance. Reimagining how we turn emissions into valuable products, we’re on a mission to create a climate positive world through the power of biochemistry and renewable energy. The company is based in Vancouver, Canada.

NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based medical solutions. The company aims to promote the use of cannabinoids as a way to alleviate discomfort caused by chronic illness, treatment side effects, or age-related conditions. Its goal is to shift the focus from treating physical disease to taking care of overall well-being by promoting the adoption of plant-based medicine. Through the use of science, ZYUS is working to establish plant-based medicine as a standard of care for disease treatment and management. Established in 2018, ZYUS is based in Saskatoon, Saskatchewan.